A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
Status:
Recruiting
Trial end date:
2023-06-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of GSK3640254 + DTG relative to
lamivudine (3TC) + DTG in treatment-naïve adult participants living with human
immunodeficiency virus (HIV)-1. The participants will be randomized to one of the three doses
of blinded GSK3640254 (100, 150, or 200 milligrams [mgs]) or a reference arm of blinded
3TC-each in combination with open label DTG.